Potential of cell-free hemoglobin and haptoglobin as prognostic markers in patients with ARDS and treatment with veno-venous ECMO.
Victoria BüngerOliver HunsickerAlexander KrannichFelix BalzerClaudia D SpiesWolfgang M KueblerSteffen Weber-CarstensMario MenkJan A GrawPublished in: Journal of intensive care (2023)
Moderate hemolysis with mCFH-levels as low as 11 mg/dl impacts mortality in patients with ARDS and therapy with veno-venous ECMO. Furthermore, a cumulative dose effect should be considered indicated by the relative therapy days with CFH-concentrations > 11 mg/dl. In addition, also Hp plasma concentrations need consideration when the injurious effect of elevated CFH is evaluated.
Keyphrases
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- cell free
- respiratory failure
- mechanical ventilation
- cardiovascular events
- risk factors
- type diabetes
- replacement therapy
- risk assessment
- coronary artery disease
- human health
- stem cells
- cardiovascular disease
- intensive care unit
- circulating tumor cells